^
    2d
    Immune receptor translocation-associated protein 1 and myeloid nuclear differentiation antigen are useful markers for the differential diagnosis of marginal zone lymphoma. (PubMed, Pathology)
    Expression of IRTA1 alone, or either IRTA1+ or MNDA+, was less frequent among MZL with plasma cell differentiation than among MZL with classical cell morphology (p=0.063 and 0.071, respectively), albeit not significantly. IRTA1 and MNDA are sensitive and specific markers for the differential diagnosis of MZL, and they may be helpful in distinguishing MZL from histologic mimics.
    Journal
    |
    CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6) • CD5 (CD5 Molecule) • MME (Membrane Metalloendopeptidase) • SOX11 (SRY-Box Transcription Factor 11) • FCER2 (Fc Fragment Of IgE Receptor II)
    3d
    Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (clinicaltrials.gov)
    P1/2, N=8, Active, not recruiting, City of Hope Medical Center | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • PAX5 (Paired Box 5) • CD5 (CD5 Molecule)
    |
    Chr t(11;14)
    |
    Venclexta (venetoclax) • Aliqopa (copanlisib)
    4d
    Dissecting Pirtobrutinib Resistance in Mantle Cell Lymphoma Through Single-Cell Multi-Omics. (PubMed, Am J Hematol)
    A stem-like malignant B cell population enriched in resistant samples exhibited features of metabolic reprogramming and epithelial-mesenchymal transition. Together, our findings highlight heterogeneous, multi-layered mechanisms of PBN resistance and suggest chromatin regulators as potential therapeutic targets to overcome PBN resistance in MCL.
    Journal
    |
    RAD21 (RAD21 Cohesin Complex Component)
    |
    Jaypirca (pirtobrutinib)
    5d
    PRMT5 inhibition sensitizes B-cell lymphoma cells to ferroptosis. (PubMed, Leukemia)
    Notably, combined treatment with the PRMT5 inhibitor GSK3326595 and DMF synergistically enhances anti-tumor activity in a patient-derived xenograft (PDX) model. These findings reveal a previously unrecognized PRMT5-ATF5-SLC7A11 axis that drives ferroptosis resistance in B-cell lymphomas and provide a strong rationale for targeting PRMT5 to potentiate ferroptosis-based therapies in relapsed or refractory disease.
    Journal
    |
    PRMT5 (Protein Arginine Methyltransferase 5) • SLC7A11 (Solute Carrier Family 7 Member 11) • ATF4 (Activating Transcription Factor 4)
    |
    pemrametostat (GSK3326595)
    5d
    Interpretable multimodal PET/CT-EHR fusion via mixture-of-experts for prognostic stratification in mantle cell lymphoma: a multicenter study. (PubMed, BMC Med)
    This interpretable PET/CT-EHR fusion framework substantially improves prognostic precision in MCL, providing a noninvasive, clinically translatable tool for risk-adapted management.
    Clinical • Journal
    |
    B2M (Beta-2-microglobulin)
    5d
    Blastoïd mantle cell lymphoma, TdT-positive: Toward a more juvenile profile? (PubMed, Ann Pathol)
    We report a 63 year-old man with bone marrow involvement by mantle cell lymphoma displaying an immunohistochemical profile CD20+, CD5+, cyclin D1+, SOX11-, with distinctive features including blastoid morphology, diffuse TdT expression, and MYC gene rearrangement. This exceptional association of blastoid morphology, TdT expression, and MYC rearrangement in mantle cell lymphoma suggests a process of tumor dedifferentiation and broadens the clinico-biological spectrum of mantle cell lymphoma, raising significant diagnostic and prognostic challenges.
    Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CCND1 (Cyclin D1) • CD5 (CD5 Molecule) • SOX11 (SRY-Box Transcription Factor 11)
    |
    TP53 mutation
    6d
    BGB-16673-102: Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader (clinicaltrials.gov)
    P1/2, N=146, Recruiting, BeiGene | Trial completion date: Sep 2027 --> Jan 2029 | Trial primary completion date: Feb 2026 --> Jan 2029
    Trial completion date • Trial primary completion date
    |
    catadegbrutinib (BGB-16673)
    6d
    GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma (clinicaltrials.gov)
    P2, N=50, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1)
    |
    CD20 positive • Chr t(11;14)
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • Jaypirca (pirtobrutinib)
    7d
    Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=20, Recruiting, New York Medical College | Trial completion date: Aug 2025 --> Aug 2027 | Trial primary completion date: Aug 2024 --> Aug 2026
    Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD34 (CD34 molecule)
    |
    Polivy (polatuzumab vedotin-piiq)
    7d
    Study carried out at multiple centers to test Glofitamab in patients with mantle cell lymphoma who did not respond well to, or relapsed after, CAR T-cell therapy. (2025-523428-39-00)
    P1/2, N=41, Not yet recruiting, Fondazione Italiana Linfomi Ets
    New P1/2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • Columvi (glofitamab-gxbm)
    8d
    CELESTIAL-301: SynKIR-310 for Relapsed/Refractory B-NHL (clinicaltrials.gov)
    P1, N=36, Recruiting, Verismo Therapeutics | N=18 --> 36
    Enrollment change • First-in-human
    |
    BCL2 (B-cell CLL/lymphoma 2)
    9d
    Soundtrack-E: A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies (clinicaltrials.gov)
    P1/2, N=408, Recruiting, AstraZeneca | N=276 --> 408 | Trial completion date: Feb 2028 --> Jun 2029
    Enrollment change • Trial completion date
    |
    CD19 (CD19 Molecule)
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Calquence (acalabrutinib) • vincristine • prednisone • surovatamig (AZD0486)